Celsion (CLSN) is out with some upbeat ThermoDox commentary, saying the HEAT study's lead European principal investigator Riccardo Lencioni has made two presentations discussing what he says are "post-hoc data that indicate ThermoDox may provide potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes." Shares +14.75% premarket. (Previous: SA contributor spars with CLSN over HEAT study)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Fri, 1:04PM)
at Benzinga.com (Fri, 11:45AM)
at MarketWatch.com (Mar 8, 2013)
at MarketWatch.com (Jan 15, 2013)
at MarketWatch.com (Dec 27, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs